Table 4 |
||||
Mean homocysteine concentration at follow up* according to treatment group and fracture outcomes | ||||
With fracture mean (standard deviation) | Without fracture mean (standard deviation) | Difference, (95% confidence interval) | P-value (paired t-test) | |
Homocysteine (micromol/L | ||||
Placebo (n = 584) | 15.7 (5.9) (n = 23) | 14.2 (6.1) (n = 561) | −1.52 (−4.08,1.04) | 0.2447 |
B-Vitamins (n =580) | 11.7 (9.6) (n = 18) | 10.5 (4.6) (n = 562) | −1.17 (−3.46,1.11) | 0.3118 |
* The difference between baseline and follow-up Homocysteine levels were also compared between patients with and without facture. The differences are not significant, either (data not shown).
Note: Only a small subset of patients (14.3%) had homocysteine levels measured at final follow up.
Gommans et al.
Gommans et al. BMC Geriatrics 2013 13:88 doi:10.1186/1471-2318-13-88